Emcure Pharmaceuticals Q4 FY26 Results: Net Profit Rises 24% To ₹243.74 Crore, Revenue Crosses ₹2,469 Crore

Emcure Pharmaceuticals reported a strong performance for the quarter ended March 2026. The company’s consolidated net profit increased 24% year-on-year to ₹243.74 crore, compared to ₹197.24 crore in the same quarter last year.

Revenue from operations also grew to ₹2,469.7 crore, up from ₹2,116.25 crore a year ago.

Strong International Business Performance

The company’s international business was the biggest growth driver in the quarter.
International sales reached ₹1,493 crore, rising 25.7% YoY, supported by growth across markets, new product launches, and expansion of existing businesses.

Domestic Business Shows Steady Growth

Domestic sales stood at ₹977 crore, growing 5.2% YoY. Growth in India was slower due to softer performance in the Zuventus portfolio and internal team reorganisation.

Read More: Zen Technologies Share Price Drops 10%; Q4 FY26 Results Show PAT Falls 69% YoY! 

Expenses And Full-Year Performance

Total expenses in Q4 increased to ₹2,142.82 crore compared to ₹1,849.7 crore last year.

For the full financial year FY26:

• Net profit rose to ₹941.27 crore from ₹707.47 crore in FY25
• Revenue increased to ₹9,203.54 crore from ₹7,896 crore in FY25

Management Commentary And Future Plans

Managing Director and CEO Satish Mehta said FY26 marked the first year of the company’s 5-year strategy and delivered strong results with revenue crossing $1 billion.

The company plans to focus on complex injectables and biosimilars through its R&D pipeline to drive future growth. The board also approved Satish Mehta’s reappointment as Managing Director for five more years from April 1, 2027, subject to shareholder approval.

Dividend Announcement

The board recommended a final dividend of ₹3.6 per share for FY26, subject to shareholder approval.

Conclusion

Emcure Pharmaceuticals delivered solid Q4 and FY26 results, led by strong international growth and improving financial performance. With continued focus on R&D and global expansion, the company aims to maintain steady long-term growth.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.